Macroglobulinemia: Difference between revisions
No edit summary |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 17: | Line 17: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 26: | Line 26: | ||
* [[Waldenström macroglobulinemia]] | * [[Waldenström macroglobulinemia]] | ||
[[Category:Blood tests]] | [[Category:Blood tests]] | ||
Latest revision as of 17:07, 9 August 2012
| Macroglobulinemia | |
| ICD-9 | 273.3 |
|---|---|
| MeSH | D008258 |
|
WikiDoc Resources for Macroglobulinemia |
|
Articles |
|---|
|
Most recent articles on Macroglobulinemia Most cited articles on Macroglobulinemia |
|
Media |
|
Powerpoint slides on Macroglobulinemia |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Macroglobulinemia |
|
Clinical Trials |
|
Ongoing Trials on Macroglobulinemia at Clinical Trials.gov Trial results on Macroglobulinemia Clinical Trials on Macroglobulinemia at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Macroglobulinemia NICE Guidance on Macroglobulinemia
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Macroglobulinemia Discussion groups on Macroglobulinemia Patient Handouts on Macroglobulinemia Directions to Hospitals Treating Macroglobulinemia Risk calculators and risk factors for Macroglobulinemia
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Macroglobulinemia |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. A plasma cell dyscrasia resembling leukemia with cells of lymphocytic, plasmacytic, or intermediate morphology, which secrete an immunoglobulin M monoclonal component. There is diffuse infiltration of bone marrow and also, in many cases, of the spleen, liver, or lymph nodes. The circulating macroglobulin produces symptoms of hyperviscosity syndrome: weakness, fatigue, bleeding disorders, and visual disturbances. Peak incidence is in the sixth and seventh decades. (Dorland, 28th ed)